Literature DB >> 21301897

Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.

Rui D S Prediger1, Argelia E Rojas-Mayorquin, Aderbal S Aguiar, Caroline Chevarin, Raymond Mongeau, Michel Hamon, Laurence Lanfumey, Elaine Del Bel, Hisako Muramatsu, José Courty, Rita Raisman-Vozari.   

Abstract

There is considerable evidence showing that the neurodegenerative processes that lead to sporadic Parkinson's disease (PD) begin many years before the appearance of the characteristic motor symptoms and that impairments in olfactory, cognitive and motor functions are associated with time-dependent disruption of dopaminergic neurotransmission in different brain areas. Midkine is a 13-kDa retinoic acid-induced heparin-binding growth factor involved in many biological processes in the central nervous system such as cell migration, neurogenesis and tissue repair. The abnormal midkine expression may be associated with neurochemical dysfunction in the dopaminergic system and cognitive impairments in rodents. Here, we employed adult midkine knockout mice (Mdk(-/-)) to further investigate the relevance of midkine in dopaminergic neurotransmission and in olfactory, cognitive and motor functions. Mdk(/-) mice displayed pronounced impairments in their olfactory discrimination ability and short-term social recognition memory with no gross motor alterations. Moreover, the genetic deletion of midkine decreased the expression of the enzyme tyrosine hydroxylase in the substantia nigra reducing partially the levels of dopamine and its metabolites in the olfactory bulb and striatum of mice. These findings indicate that the genetic deletion of midkine causes a partial loss of dopaminergic neurons and depletion of dopamine, resulting in olfactory and memory deficits with no major motor impairments. Therefore, Mdk(-/-) mice may represent a promising animal model for the study of the early stages of PD and for testing new therapeutic strategies to restore sensorial and cognitive processes in PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301897     DOI: 10.1007/s00702-010-0568-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  64 in total

Review 1.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

Review 2.  Neuroprotective and neurorestorative strategies for Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

3.  Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour.

Authors:  E Nakamura; K Kadomatsu; S Yuasa; H Muramatsu; T Mamiya; T Nabeshima; Q W Fan; K Ishiguro; T Igakura; S Matsubara; T Kaname; M Horiba; H Saito; T Muramatsu
Journal:  Genes Cells       Date:  1998-12       Impact factor: 1.891

4.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

5.  Influence of the D-2 dopamine receptor agonist quinpirole on the odor detection performance of rats before and after spiperone administration.

Authors:  R L Doty; J M Risser
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 6.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

Authors:  Anthony H V Schapira; C Warren Olanow
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

7.  Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.

Authors:  Rui D S Prediger; Daniel Rial; Rodrigo Medeiros; Cláudia P Figueiredo; Richard L Doty; Reinaldo N Takahashi
Journal:  Ann N Y Acad Sci       Date:  2009-07       Impact factor: 5.691

8.  Norepinephrine modulation of social memory: evidence for a time-dependent functional recovery of behavior.

Authors:  M G Griffin; G T Taylor
Journal:  Behav Neurosci       Date:  1995-06       Impact factor: 1.912

9.  Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration.

Authors:  R L Doty; D A Deems; S Stellar
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

10.  Olfactory deprivation increases dopamine D2 receptor density in the rat olfactory bulb.

Authors:  K M Guthrie; J M Pullara; J F Marshall; M Leon
Journal:  Synapse       Date:  1991-05       Impact factor: 2.562

View more
  12 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  The midkine family of growth factors: diverse roles in nervous system formation and maintenance.

Authors:  C Winkler; S Yao
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 3.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Midkine in the mouse ventral tegmental area limits ethanol intake and Ccl2 gene expression.

Authors:  H Chen; D He; A W Lasek
Journal:  Genes Brain Behav       Date:  2017-05-02       Impact factor: 3.449

5.  Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area.

Authors:  Daniel García-Pérez; M Luisa Laorden; M Victoria Milanés
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

6.  CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Authors:  Fabrine Sales Massafera Tristão; Márcio Lazzarini; Sabine Martin; Majid Amar; Walter Stühmer; Frank Kirchhoff; Lucas Araújo Caldi Gomes; Laurance Lanfumey; Rui D Prediger; Julia E Sepulveda; Elaine A Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-24       Impact factor: 3.911

7.  Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.

Authors:  Fabrine S M Tristão; Majid Amar; Ines Latrous; Elaine A Del-Bel; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-05-21       Impact factor: 3.911

8.  The temporal expression pattern of alpha-synuclein modulates olfactory neurogenesis in transgenic mice.

Authors:  Sebastian R Schreglmann; Martin Regensburger; Edward Rockenstein; Eliezer Masliah; Wei Xiang; Jürgen Winkler; Beate Winner
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 9.  Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus.

Authors:  Celia González-Castillo; Daniel Ortuño-Sahagún; Carolina Guzmán-Brambila; Mercè Pallàs; Argelia Esperanza Rojas-Mayorquín
Journal:  Front Cell Neurosci       Date:  2015-01-08       Impact factor: 5.505

10.  Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease.

Authors:  Daniel Rial; Adalberto A Castro; Nuno Machado; Pedro Garção; Francisco Q Gonçalves; Henrique B Silva; Angelo R Tomé; Attila Köfalvi; Olga Corti; Rita Raisman-Vozari; Rodrigo A Cunha; Rui D Prediger
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.